Generic Name and Formulations:
Cevimeline HCl 30mg; caps.
Indications for EVOXAC:
Dry mouth associated with Sjogren's syndrome.
30mg three times daily.
Uncontrolled asthma. When miosis is undesirable (eg, acute iritis, narrow-angle glaucoma).
History of cardiovascular disease. Controlled asthma. Chronic bronchitis. COPD. History of nephrolithiasis or cholelithiasis. CYP2D6 deficiency. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiated by CYP2D6 and CYP3A3/4 inhibitors. Possible conduction disturbances with β-adrenergic antagonists. Additive effects with parasympathomimetics. May interfere with antimuscarinics.
Excessive sweating (dehydration may develop; drink extra water), rhinitis, excessive salivation, UTI, cough, arthralgia, fatigue, insomnia, hot flushes, GI upset, visual disturbances (eg, blurring, decreased visual acuity), others.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking